PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 33397369-10 2021 We discuss the PPARalpha-related drugs in clinical applications and facts related to the drugs that may be considered as risky (such as fenofibrate, bezafibrate, clofibrate) or safe (pemafibrate, metformin and glucagon-like peptide 1-receptor agonists) or having the potential (sodium-glucose co-transporter 2 inhibitor) in treating DCM. Bezafibrate 149-160 peroxisome proliferator activated receptor alpha Homo sapiens 15-24 33031833-3 2021 We hypothesized that bezafibrate, a broad peroxisome proliferator-activated receptor (PPAR) agonist, relieves cholestasis-associated itch by alleviating hepatobiliary injury. Bezafibrate 21-32 peroxisome proliferator activated receptor alpha Homo sapiens 42-84 33031833-3 2021 We hypothesized that bezafibrate, a broad peroxisome proliferator-activated receptor (PPAR) agonist, relieves cholestasis-associated itch by alleviating hepatobiliary injury. Bezafibrate 21-32 peroxisome proliferator activated receptor alpha Homo sapiens 86-90 34713454-4 2022 However, two clinical trials have been recently undertaken which target the mitochondrial pathology of this disease: a study to examine the effects of elamipretide, a cardiolipin targeted agent, and a study to examine the effects of bezafibrate, a peroxisome proliferator-activated receptor (PPAR) agonist. Bezafibrate 233-244 peroxisome proliferator activated receptor alpha Homo sapiens 292-296 34335707-4 2021 In vitro, PC cell lines PANC-1 and AsPC-1 were cultured, and MTT and flow cytometry were performed to observe the effects of pan-PPAR agonist bezafibrate and EZH2 selective inhibitor GSK126 on cell viability and apoptosis. Bezafibrate 142-153 peroxisome proliferator activated receptor alpha Homo sapiens 129-133 22550474-4 2012 Expression of either functional or dominant negative hPPARdelta blocked bezafibrate-induced PPARalpha-dependent hepatomegaly and blocked the effect of bezafibrate on the transcription of PPARalpha target genes. Bezafibrate 72-83 peroxisome proliferator activated receptor alpha Homo sapiens 92-101 22550474-4 2012 Expression of either functional or dominant negative hPPARdelta blocked bezafibrate-induced PPARalpha-dependent hepatomegaly and blocked the effect of bezafibrate on the transcription of PPARalpha target genes. Bezafibrate 151-162 peroxisome proliferator activated receptor alpha Homo sapiens 187-196 35563117-0 2022 Functional and Structural Insights into Human PPARalpha/delta/gamma Subtype Selectivity of Bezafibrate, Fenofibric Acid, and Pemafibrate. Bezafibrate 91-102 peroxisome proliferator activated receptor alpha Homo sapiens 46-61 33498265-7 2021 Importantly, PPAR agonists (rosiglitazone and bezafibrate) rescued the LD-associated phenotype in LPL KD microglia. Bezafibrate 46-57 peroxisome proliferator activated receptor alpha Homo sapiens 13-17 31163124-8 2019 PPARalpha antagonist (MK886), PPARbeta antagonist (GSK0660), and PPARgamma antagonist (GW9662) reversed the protection of bezafibrate in NRK-52E, and abrogated the up-regulation of CYP4A-20-HETE produced by bezafibrate. Bezafibrate 122-133 peroxisome proliferator activated receptor alpha Homo sapiens 0-9 31713023-10 2020 These include FXR agonists, ASBT inhibitors, and PPAR agonists such as bezafibrate and fenofibrate. Bezafibrate 71-82 peroxisome proliferator activated receptor alpha Homo sapiens 49-53 32629063-9 2020 Importantly, the anemia could be rescued through enhanced PPAR signaling in vivo via either overexpression of Pgc1beta or Bezafibrate administration. Bezafibrate 122-133 peroxisome proliferator activated receptor alpha Homo sapiens 58-62 30515714-6 2019 Moreover, it has been evidenced that free radical scavengers and the pan-PPAR agonist bezafibrate are able to prevent most deleterious effects elicited by sulfite on the brain. Bezafibrate 86-97 peroxisome proliferator activated receptor alpha Homo sapiens 73-77 30315479-1 2019 Bezafibrate (BZ) regulates mitochondrial biogenesis by activation of PPAR"s receptors and enhancing the level of PGC-1alpha coactivator. Bezafibrate 0-11 peroxisome proliferator activated receptor alpha Homo sapiens 69-73 30315479-1 2019 Bezafibrate (BZ) regulates mitochondrial biogenesis by activation of PPAR"s receptors and enhancing the level of PGC-1alpha coactivator. Bezafibrate 13-15 peroxisome proliferator activated receptor alpha Homo sapiens 69-73 30315479-2 2019 In this report, we investigated the effect of BZ on the expression of genes (1) that are linked to different pathways involved in mitochondrial biogenesis, e.g., regulated by PPAR"s receptors or PGC-1alpha coactivator, and (2) involved in neuronal or astroglial fate, during neural differentiation of hiPSC. Bezafibrate 46-48 peroxisome proliferator activated receptor alpha Homo sapiens 175-179 26333891-1 2015 OBJECTIVES: The aim of this study was to compare the ketogenic effect of the peroxisome proliferator-activated receptor-alpha stimulator, bezafibrate (BEZA), alone or in combination with medium-chain triacylglycerols (MCTs) in healthy adults. Bezafibrate 138-149 peroxisome proliferator activated receptor alpha Homo sapiens 77-125 30143538-3 2018 In the current study, we examined the molecular mechanism of the synergistic effects of bezafibrate, an agonist of PGC-1alpha/ PPAR complexes, which enhanced the tumoricidal effects of PD-1 blockade. Bezafibrate 88-99 peroxisome proliferator activated receptor alpha Homo sapiens 127-131 29928160-6 2018 Other alternatives, including the peroxisome proliferator-activated receptor (PPAR)-alpha agonists fenofibrate and bezafibrate, may also improve liver biochemistries in PBC patients with an inadequate response to UDCA, but further study is needed to demonstrate their safety and long-term efficacy. Bezafibrate 115-126 peroxisome proliferator activated receptor alpha Homo sapiens 34-89 28097454-1 2017 Bezafibrate (BF) is a peroxisome proliferator-activated receptor (PPAR) agonist used as a lipid-lowering agent to treat both the familial or acquired combined forms of hyperlipidemia. Bezafibrate 0-11 peroxisome proliferator activated receptor alpha Homo sapiens 22-64 28097454-1 2017 Bezafibrate (BF) is a peroxisome proliferator-activated receptor (PPAR) agonist used as a lipid-lowering agent to treat both the familial or acquired combined forms of hyperlipidemia. Bezafibrate 0-11 peroxisome proliferator activated receptor alpha Homo sapiens 66-70 28097454-1 2017 Bezafibrate (BF) is a peroxisome proliferator-activated receptor (PPAR) agonist used as a lipid-lowering agent to treat both the familial or acquired combined forms of hyperlipidemia. Bezafibrate 13-15 peroxisome proliferator activated receptor alpha Homo sapiens 22-64 28097454-1 2017 Bezafibrate (BF) is a peroxisome proliferator-activated receptor (PPAR) agonist used as a lipid-lowering agent to treat both the familial or acquired combined forms of hyperlipidemia. Bezafibrate 13-15 peroxisome proliferator activated receptor alpha Homo sapiens 66-70 26467040-7 2016 Hypolipidemic drugs, such as bezafibrate, known activators of the peroxisome proliferator-activated receptor alpha (PPARalpha), induce both the PANK1 gene and miR107 (~2.5-fold) in primary human hepatocytes. Bezafibrate 29-40 peroxisome proliferator activated receptor alpha Homo sapiens 66-114 26467040-7 2016 Hypolipidemic drugs, such as bezafibrate, known activators of the peroxisome proliferator-activated receptor alpha (PPARalpha), induce both the PANK1 gene and miR107 (~2.5-fold) in primary human hepatocytes. Bezafibrate 29-40 peroxisome proliferator activated receptor alpha Homo sapiens 116-125 26467040-9 2016 CYP2C8 promoter activity was increased by ectopic expression of PPARalpha in HepG2 cells, with a further increase after bezafibrate (~18-fold), 4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio acetic acid (~10-fold) treatment, or the antidiabetic drug rosiglitazone, all known PPAR activators. Bezafibrate 120-131 peroxisome proliferator activated receptor alpha Homo sapiens 64-73 26467040-9 2016 CYP2C8 promoter activity was increased by ectopic expression of PPARalpha in HepG2 cells, with a further increase after bezafibrate (~18-fold), 4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio acetic acid (~10-fold) treatment, or the antidiabetic drug rosiglitazone, all known PPAR activators. Bezafibrate 120-131 peroxisome proliferator activated receptor alpha Homo sapiens 64-68 26333891-1 2015 OBJECTIVES: The aim of this study was to compare the ketogenic effect of the peroxisome proliferator-activated receptor-alpha stimulator, bezafibrate (BEZA), alone or in combination with medium-chain triacylglycerols (MCTs) in healthy adults. Bezafibrate 151-155 peroxisome proliferator activated receptor alpha Homo sapiens 77-125 25539886-13 2015 An in vitro examination demonstrated TCchem attenuated nitric oxide production and PPARalpha activity in HUVECs, which was partially improved by treatment with bezafibrate. Bezafibrate 160-171 peroxisome proliferator activated receptor alpha Homo sapiens 83-92 25134759-3 2015 We investigated the effect of bezafibrate, a peroxisome proliferator-activated receptor alpha agonist, on circulating CD14(+)CD16(+) monocytes in patients with type 2 diabetes. Bezafibrate 30-41 peroxisome proliferator activated receptor alpha Homo sapiens 45-93 24606795-21 2014 Several pharmacological strategies to trigger these signaling cascades, according to these authors, are the use of bezafibrate to activate the PPAR-PGC-1alpha axis, the activation of AMPK by resveratrol and the use of Sirt1 agonists such as quercetin or resveratrol. Bezafibrate 115-126 peroxisome proliferator activated receptor alpha Homo sapiens 143-147 24950685-5 2014 By employing TCDD ( an AhR agonist), rosiglitazone (a PPARgamma agonist) or bezafibrate (a PPARalpha agonist), the presence of a functional AhR and PPAR cascade was confirmed in KGN cells. Bezafibrate 76-87 peroxisome proliferator activated receptor alpha Homo sapiens 91-100 24302581-8 2014 Moreover, as bezafibrate is a well-tolerated clinically approved drug used for managing lipidemia, our findings provide an immediate cue for clinical studies to evaluate the utility of PPARalpha ligands as safe agents for the treatment of lung cancer in humans. Bezafibrate 13-24 peroxisome proliferator activated receptor alpha Homo sapiens 185-194 24606795-40 2014 As strategies to induce PGC-1alpha activation, these authors remark the possibility to activate Sirt1 with resveratrol, to use PPAR agonists such as pioglitazone, rosiglitazone, fenofibrate and bezafibrate. Bezafibrate 194-205 peroxisome proliferator activated receptor alpha Homo sapiens 127-131 24511666-4 2013 Among these fibrates, the binding activity of fenofibrate to PPAR-alpha is stronger than that of bezafibrate. Bezafibrate 97-108 peroxisome proliferator activated receptor alpha Homo sapiens 61-71 23897856-7 2014 We further demonstrate that treatment with a PPAR-alpha agonist, bezafibrate, is able to reverse the miR-27b-induced lipid accumulation in Huh7 cells. Bezafibrate 65-76 peroxisome proliferator activated receptor alpha Homo sapiens 45-55 19429239-6 2009 Other PPAR ligands like the PPARgamma agonist, troglitazone; the PPARalpha agonist, Wy-14643, and bezafibrate were also able to inhibit TGF-beta-induced CTGF. Bezafibrate 98-109 peroxisome proliferator activated receptor alpha Homo sapiens 6-10 20404010-1 2010 Our objective was to determine whether bezafibrate, a hypotriglyceridemic drug and peroxisome proliferator-activated receptor (PPAR)-alpha agonist, is ketogenic and increases fatty acid oxidation in humans. Bezafibrate 39-50 peroxisome proliferator activated receptor alpha Homo sapiens 83-138 20404010-8 2010 Thus, in hypertriglyceridemic individuals, bezafibrate is mildly ketogenic and significantly changes fatty acid metabolism, effects that may be linked to PPARalpha stimulation and to moderately improved glucose metabolism. Bezafibrate 43-54 peroxisome proliferator activated receptor alpha Homo sapiens 154-163 19667161-15 2009 Simultaneous treatment with the PPAR ligands bezafibrate or ALA resulted in an up to 6-fold reduction of the 1,25(OH)2D3-induced elevation of the 1alpha,25-dihydroxyvitamin D3-24-hydroxylase (CYP24A1) expression. Bezafibrate 45-56 peroxisome proliferator activated receptor alpha Homo sapiens 32-36 22447153-5 2012 In this paper we demonstrate that bezafibrate, a PPAR pan agonist used for the treatment of patients with hyperlipidaemia reduces VLCFA levels in X-ALD fibroblasts. Bezafibrate 34-45 peroxisome proliferator activated receptor alpha Homo sapiens 49-53 21215149-1 2010 OBJECTIVE: To investigate the effect of peroxisome proliferator-activated receptor (PPAR)alpha agonist bezafibrate and oxidized low density lipoprotein (ox-LDL) on fibroblast growth factor 21 (FGF21) expression and apoptosis in cardiac endothelial cells. Bezafibrate 103-114 peroxisome proliferator activated receptor alpha Homo sapiens 84-94 19683050-0 2010 Bezafibrate induces myotoxicity in human rhabdomyosarcoma cells via peroxisome proliferator-activated receptor alpha signaling. Bezafibrate 0-11 peroxisome proliferator activated receptor alpha Homo sapiens 68-116 19683050-3 2010 This study was designed to investigate the effects of bezafibrate as a PPARalpha agonist on human embryo rhabdomyosarcoma (RD) cells and possible mechanisms responsible for bezafibrate-mediated myopathy. Bezafibrate 54-65 peroxisome proliferator activated receptor alpha Homo sapiens 71-80 19683050-5 2010 Bezafibrate at toxic doses of 300 and 1000microM upregulated PPARalpha at the mRNA level, counteracted by a PPARalpha antagonist (MK886). Bezafibrate 0-11 peroxisome proliferator activated receptor alpha Homo sapiens 61-70 19683050-5 2010 Bezafibrate at toxic doses of 300 and 1000microM upregulated PPARalpha at the mRNA level, counteracted by a PPARalpha antagonist (MK886). Bezafibrate 0-11 peroxisome proliferator activated receptor alpha Homo sapiens 108-117 19683050-6 2010 Bezafibrate at a toxic dose induced typical apoptotic characteristics related to the inhibition of phosphorylation of Akt which was blocked by PPARalpha antagonist. Bezafibrate 0-11 peroxisome proliferator activated receptor alpha Homo sapiens 143-152 19124612-1 2009 The triglyceride-lowering effect of bezafibrate in humans has been attributed to peroxisome proliferator-activated receptor (PPAR) alpha activation based on results from rodent studies. Bezafibrate 36-47 peroxisome proliferator activated receptor alpha Homo sapiens 81-123 19124612-1 2009 The triglyceride-lowering effect of bezafibrate in humans has been attributed to peroxisome proliferator-activated receptor (PPAR) alpha activation based on results from rodent studies. Bezafibrate 36-47 peroxisome proliferator activated receptor alpha Homo sapiens 125-129 18230960-16 2008 In addition, bezafibrate as a pan-PPAR activator has clearly demonstrated beneficial pleiotropic effects related to glucose metabolism, insulin sensitivity and pancreatic beta cell protection. Bezafibrate 13-24 peroxisome proliferator activated receptor alpha Homo sapiens 34-38 18211970-2 2008 OBJECTIVE: We tested whether bezafibrate, a drug acting as a peroxisome proliferator-activated receptor (PPAR) agonist, could stimulate RC capacities. Bezafibrate 29-40 peroxisome proliferator activated receptor alpha Homo sapiens 105-109 15258199-8 2004 These findings suggest that BF may enhance the capacity of human hepatocytes to direct PC into bile canaliculi via PPARalpha-mediated redistribution of ABCB4 to the canalicular membrane. Bezafibrate 28-30 peroxisome proliferator activated receptor alpha Homo sapiens 115-124 16168052-14 2005 However, from a biochemical point of view, bezafibrate is a PPAR ligand with a relatively low potency. Bezafibrate 43-54 peroxisome proliferator activated receptor alpha Homo sapiens 60-64 15936983-3 2005 Indeed, treatment with the PPARalpha-PPARbeta/delta agonist bezafibrate led to the up-regulation of I-BABP mRNA levels in the human intestine-derived Caco-2 cells. Bezafibrate 60-71 peroxisome proliferator activated receptor alpha Homo sapiens 27-36 17010686-8 2007 Bezafibrate and fenofibrate, which non-discriminately activate all PPAR isoforms, significantly inhibited the formation of multinucleated osteoclasts from PBMC in vitro. Bezafibrate 0-11 peroxisome proliferator activated receptor alpha Homo sapiens 67-71 16226225-1 2005 Fibrates such as bezafibrate, gemfibrozil, clofibric acid, ciprofibrate and fenofibrate, are ligands for peroxisome proliferator-activated receptor alpha (PPARalpha), and are used as therapeutic agents in the treatment of hyperlipidemia. Bezafibrate 17-28 peroxisome proliferator activated receptor alpha Homo sapiens 105-153 16226225-1 2005 Fibrates such as bezafibrate, gemfibrozil, clofibric acid, ciprofibrate and fenofibrate, are ligands for peroxisome proliferator-activated receptor alpha (PPARalpha), and are used as therapeutic agents in the treatment of hyperlipidemia. Bezafibrate 17-28 peroxisome proliferator activated receptor alpha Homo sapiens 155-164 15953354-8 2005 These experiments revealed that 24(S)OH-cholesterol (a LXR agonist), bezafibrate (a PPARalpha agonist), or pioglitazone (a PPARgamma agonist) resulted in down-regulation of EL mRNA and protein levels. Bezafibrate 69-80 peroxisome proliferator activated receptor alpha Homo sapiens 84-93 15800711-6 2005 Cell lines were treated by ligands of PPARalpha (bezafibrate, gemfibrozil) and PPARgamma (ciglitazone). Bezafibrate 49-60 peroxisome proliferator activated receptor alpha Homo sapiens 38-47 15521013-5 2004 RESULTS: We show that peroxisome proliferator-activated receptor-alpha agonists (WY-14643, bezafibrate, clofibrate, and phthalate) induce human cytochrome P450 1A1 gene expression, whereas 2,4-thiazolidinedione, a specific peroxisome proliferator-activated receptor-gamma agonist, represses it. Bezafibrate 91-102 peroxisome proliferator activated receptor alpha Homo sapiens 22-70 14523052-3 2004 Bezafibrate (BF), a hypolipidemic drug and a peroxisome proliferator activator receptor-alpha (PPARalpha) agonist, specifically increased hPANK1alpha mRNA expression in human hepatoblastoma (HepG2) cells as a function of time and dose of the drug, compared with hPANK1beta, hPANK2, and hPANK3, which did not significantly increase. Bezafibrate 0-11 peroxisome proliferator activated receptor alpha Homo sapiens 95-104 14982965-3 2004 In addition, [(3)H]NS-220 bound to the ligand-binding domain of human PPARalpha with a K(D) value of 1.85 x 10(-7) M. Fenofibric acid and bezafibrate showed weak agonist activity for PPARalpha (EC(50), 2-8 x 10(-5) M), with poor subtype selectivity. Bezafibrate 138-149 peroxisome proliferator activated receptor alpha Homo sapiens 70-79 14523052-3 2004 Bezafibrate (BF), a hypolipidemic drug and a peroxisome proliferator activator receptor-alpha (PPARalpha) agonist, specifically increased hPANK1alpha mRNA expression in human hepatoblastoma (HepG2) cells as a function of time and dose of the drug, compared with hPANK1beta, hPANK2, and hPANK3, which did not significantly increase. Bezafibrate 13-15 peroxisome proliferator activated receptor alpha Homo sapiens 95-104 12595494-6 2003 Activation of PPARgamma with the agonist prostaglandin J2 (10 micro M) and of PPARalpha with either bezafibrate (100 micro M) or Wy14643 (100 micro M) both increased LXRalpha and ABCA1 gene expression also and enhanced apoA1-mediated cholesterol efflux from lipid-loaded cells, even in the presence of IL-1beta. Bezafibrate 100-111 peroxisome proliferator activated receptor alpha Homo sapiens 78-87 14615970-0 2003 Bezafibrate induces a mitochondrial derangement in human cell lines: a PPAR-independent mechanism for a peroxisome proliferator. Bezafibrate 0-11 peroxisome proliferator activated receptor alpha Homo sapiens 71-75 12759900-2 2003 We compared the effects of three PPAR activators (bezafibrate, fenofibrate, and troglitazone) on the mRNA levels of genes involved in lipid metabolism in primary human macrophages and macrophage-derived foam cells. Bezafibrate 50-61 peroxisome proliferator activated receptor alpha Homo sapiens 33-37 11422732-6 2001 PPARalpha is the molecular target of the hypolipidemic fibrates including bezafibrate and clofibrate. Bezafibrate 74-85 peroxisome proliferator activated receptor alpha Homo sapiens 0-9 12000972-5 2002 PPAR-alpha ligands (e.g., clofibrate and benzofibrate) modulate lipoprotein metabolism, and affect inflammation and coagulation cascade. Bezafibrate 41-53 peroxisome proliferator activated receptor alpha Homo sapiens 0-10 10753637-5 2000 However, PPAR-alpha agonist (bezafibrate) and other prostanoids (PGE(2), PGF(2alpha)) did not induce apoptosis. Bezafibrate 29-40 peroxisome proliferator activated receptor alpha Homo sapiens 9-19